2011 Leads Training 
European Pharmaceutical Review
MARCH 8, 2023
Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia, and then moved to the US where she completed her Internal Medicine residency training. After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health.
European Pharmaceutical Review
DECEMBER 14, 2023
Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 Lane S, Lynn E, Shakir S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 6, 2022
The process is followed by computationally guided mutagenesis or evolution of the antibody sequence (hit to lead, or H2L, optimisation) to improve the binding and other properties. Consequently, the lead optimisation or molecular evolution offerings in the space are relatively more common among the start-ups. Disclosed Funding.
Healthcare Success
JANUARY 25, 2023
The rate of injuries from violent attacks against medical professionals grew by 63% from 2011 to 2018. Porath also found that technology overuse leads to increased exposure to negativity and misinformation. Offer de-escalation training De-escalation is not taught in medical or nursing school, but it should be.
pharmaphorum
AUGUST 22, 2022
Health Innovation Fund concentrates its investments on highly productive technologies, hoping to create more personalised care that will lead to better outcomes. “Effectively, they create antibodies that can train one’s immune system to go after a specific cancer cell. Investment strategies. About the author .
pharmaphorum
OCTOBER 12, 2022
Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Since 2017, Debiopharm has invested in 14 digital health companies, typically leading the investment rounds.
PM360
JUNE 11, 2022
Furthermore, Cactus Life Sciences leveraged these findings at a recent training session where they received more feedback and insights into the minds of Medical Affairs professionals and their current work with patients. “It The risk of not including patients in all of what we do is getting bigger than the risk of including patients.”.
Expert insights. Personalized for you.
52 
Let's personalize your content